Actinium Pharmaceuticals Inc (ATNM) |
|
7.57 -0.23 (-2.95%)
|
04-16 03:18 |
|
Open: |
7.75 |
Pre. Close: |
7.8 |
|
High:
|
7.81 |
Low:
|
7.53 |
|
Volume:
|
126,234 |
Market Cap:
|
146M |
|
|
|
|
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.832 - 7.875 |
7.875 - 7.911 |
|
Low:
|
7.397 - 7.458 |
7.458 - 7.507 |
|
Close:
|
7.481 - 7.571 |
7.571 - 7.644 |
|
Technical analysis |
as of: 2021-04-15 4:54:54 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 10.20 One year: 11.07 |
| Support: |
Support1: 7.52 Support2: 6.26 |
| Resistance: |
Resistance1: 8.73 Resistance2: 9.48 |
| Pivot: |
7.99 |
| Moving Average: |
MA(5): 7.77 MA(20): 8.15
MA(100): 9.10 MA(250): 9.63  |
| MACD: |
MACD(12,26): -0.21 Signal(9): -0.16 |
| Stochastic oscillator: |
%K(14,3): 9.40 %D(3): 13.34 |
| RSI: |
RSI(14): 37.89 |
| 52-week: |
High: 19.47 Low: 4.71 Change(%): 17.4 |
| Average Vol(K): |
3-Month: 36941 10-Days: 29062 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ATNM has closed above bottom band by 15.0%. Bollinger Bands are 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to ATNM's normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 07 Apr 2021
We Think Actinium Pharmaceuticals (NYSEMKT:ATNM) Can Afford To Drive Business Growth - Nasdaq
Mon, 05 Apr 2021
What Kind Of Shareholders Hold The Majority In Actinium Pharmaceuticals, Inc.'s (NYSEMKT:ATNM) Shares? - Simply Wall St
Thu, 01 Apr 2021
Do Analysts Agree Thursday on Actinium Pharmaceuticals Inc (ATNM) Stock's Target Price? - InvestorsObserver
Thu, 01 Apr 2021
The Math Shows VXF Can Go To $194 - Nasdaq
Wed, 31 Mar 2021
Actinium to Participate in the Cell & Gene Meeting on the Mediterranean - PRNewswire
Thu, 25 Mar 2021
Should You Buy Actinium Pharmaceuticals Inc (ATNM) Stock After it Is Lower By 3.57% in a Week? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
14 |
| Shares Float (M) |
19 |
|
% Held by Insiders
|
1.61 |
|
% Held by Institutions
|
17.11 |
|
Shares Short (K)
|
873 |
|
Shares Short P. Month (K)
|
702 |
Stock Financials |
|
EPS
|
-1.830 |
|
EPS Est This Year
|
-0.400 |
|
EPS Est Next Year
|
-0.250 |
|
Book Value (p.s.)
|
3.500 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-35.8 |
|
Return on Equity (ttm)
|
-66.3 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.615 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-22 |
|
Levered Free Cash Flow (M)
|
-15 |
Stock Valuations |
|
PE Ratio
|
-4.14 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.16 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-4.76 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2020-08-10 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
